Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021

The Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA ' s Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18-49 years.
Source: CDC Morbidity and Mortality Weekly Report - Category: American Health Tags: Advisory Committee on Immunization Practices (ACIP) MMWR Morbidity & Mortality Weekly Report COVID-19 Coronavirus Disease 2019 Source Type: news